title: Hybrid cholecystokinin (CCK) antagonists: new implications in the design and modification of CCK antagonists.
authors.affiliation: Neuroscience Research Division, Abbott Laboratories, Abbott Park, Illinois 60064.
authors.forename: J F
authors.initials: JF
authors.lastname: Kerwin
authors.forename: A M
authors.initials: AM
authors.lastname: Nadzan
authors.forename: H
authors.initials: H
authors.lastname: Kopecka
authors.forename: C W
authors.initials: CW
authors.lastname: Lin
authors.forename: T
authors.initials: T
authors.lastname: Miller
authors.forename: D
authors.initials: D
authors.lastname: Witte
authors.forename: S
authors.initials: S
authors.lastname: Burt
mesh_terms: D001569:Benzodiazepines / Q000138:chemical synthesis / Q000494:pharmacology*; D001570:Benzodiazepinones / Q000138:chemical synthesis / Q000494:pharmacology; D055598:Chemical Phenomena; D002621:Chemistry; D002766:Cholecystokinin / Q000037:antagonists & inhibitors*; D020109:Devazepide; D015195:Drug Design; D005973:Glutamine / Q000031:analogs & derivatives; D008968:Molecular Conformation; D011377:Proglumide / Q000031:analogs & derivatives / Q000138:chemical synthesis / Q000494:pharmacology; D011949:Receptors, Cholecystokinin / Q000187:drug effects; D013237:Stereoisomerism; D013329:Structure-Activity Relationship
chemical_list: D001570:Benzodiazepinones; D011949:Receptors, Cholecystokinin; D005973:Glutamine; D001569:Benzodiazepines; D002766:Cholecystokinin; D011377:Proglumide; D020109:Devazepide; C048181:lorglumide